U.S. News and the quiet arrival of a GLP-1 telehealth referee

What U.S. News Actually Measured, and Why Semaglutide Online Searches Keep Climbing#

The fox does not need a stopwatch to know which trail is freshest, it reads the scent and moves. Marketers chasing GLP-1 telehealth patients have had no equivalent instinct to lean on, because until this week nobody independent had actually scored the platforms prescribing Wegovy, Zepbound and Ozempic online. That changed on 12 August 2026, when U.S. News & World Report published its first-ever Best GLP-1 Telehealth Platforms ratings, a debut scorecard for a category that has spent three years growing largely unsupervised.

Search demand tells the same story from a different angle. Every month, 4,400 searches land on semaglutide online, the generic name behind Wegovy and Ozempic, against a difficulty score of just 1 out of 100, next to nobody competing for that exact phrase. That gap, huge demand and almost no rivals in the field, is the kind of quiet quarry a sharp fox spots long before the rest of the pack lifts its nose, and it says plenty about why an independent referee for this category was overdue.

Until this week, a prospective patient had only two places to look: a platform's own marketing, or a scattering of app-store reviews with no shared methodology behind them. U.S. News has run trusted, weighted rankings across hospitals and universities for decades. GLP-1 telehealth, a category now worth billions of dollars in annual prescriptions, has had nothing comparable until 12 August 2026, a strange gap for an industry this large and this scrutinised to have gone without.

Twenty platforms were evaluated, all of them offering FDA-approved, brand-name GLP-1 medicines rather than the compounded copies that have dogged the category's reputation. U.S. News built the scorecard around six weighted pillars: clinical support worth 25% of the total, screening rigour worth 20%, transparency worth 17%, insurance assistance worth 15%, supplemental care worth 13%, and overall customer satisfaction worth 10%, each scored on a five-point scale. That weighting tells a marketer exactly where the judges' attention sits, and it is not on satisfaction surveys, it is on whether a platform screens patients properly before it prescribes.

The six pillars, weighted#

The scale behind the scoring is bigger than a typical 'best of' roundup. U.S. News and its research partners collected 14,161 data points and gathered feedback from 1,251 US adults who had used a GLP-1 telehealth platform in the previous twelve months, surveyed by PureSpectrum between May and July 2026. Compounded-only providers were shut out entirely: U.S. News & World Report states plainly that 'companies that only offer compounded GLP-1 medications were not included in our analysis,' though hybrid platforms are still scored on their branded offering alone.

For a patient searching best glp-1 online, or simply searching semaglutide online, that insurance assistance pillar is not a footnote, it is the deciding factor. Millions of would-be patients search glp-1 without insurance every month precisely because list prices without cover run into four figures a month, and a platform that cannot explain savings cards, prior authorisation or manufacturer coupons in plain language will score poorly on transparency long before satisfaction even enters the picture. That is the trail marketers now have to follow, whether they like being followed or not.

Why This Launch Lands at the Worst Possible Moment#

Ratings launches are usually genial, harmless things: a badge, a press release, a slow news day filled. This one is different, because it arrives six weeks after a study in JAMA put real numbers on how loosely the GLP-1 telehealth prowl has actually been conducted. Researchers from Yale School of Medicine, writing in JAMA, ran a secret-shopper study between August and December 2025, soliciting GLP-1 prescriptions from 49 websites, seventeen compounded-only, five branded-only, twenty-seven offering both, then simply recorded what happened next.

What happened next should worry anyone running a GLP-1 telehealth brand. Forty-five of the 49 sites, 91.8%, issued a prescription. Only 26.5% required a video visit and a mere 6.1% required so much as a phone call before medication shipped. Four sites in five had no video assessment at all, and 8.2% offered no opportunity to ask a clinician a single question. Two compounded prescriptions were issued in five minutes or less. Nine sites, a fifth of the sample, prescribed despite missing the full-body photos their own intake forms required.

Auto-shipping compounds the risk. Thirty-four of forty-five prescribing sites, 75.6%, mailed medication without any patient confirmation step between prescription and parcel. Combine that with the fifth of sites that prescribed despite missing the full-body photographs their own intake process required, and the picture is less 'telehealth' than 'vending machine with a waiting period'. That is precisely the online glp-1 prescription pathway sitting behind every semaglutide online search, and the one U.S. News is now scoring against, whether platforms asked to be scored or not.

That is the honest anatomy of a prescription at the low end of the market: a form, a photo, and a parcel, with the clinician often reduced to a formality. Against that backdrop, a scored, weighted, independently published ratings system is not neutral consumer journalism, it is the first external referee this category has ever had. Every platform that clears the screening-rigour pillar with a real video visit and a real question is quietly proving it is not one of the 91.8%.

A fox that hunts carelessly does not stay fed for long, and a platform that ships medication into a moonlit inbox without so much as a video call is hunting carelessly. The ratings are simply the first hedgerow anyone has built around that quarry.

The FDA's Compounding Crackdown Redraws the Field#

Underneath the ratings sits a regulatory current pulling the whole category toward branded medicine anyway. On 30 April 2026, the FDA proposed removing semaglutide, tirzepatide and liraglutide from its 503B Bulks List, the mechanism that lets outsourcing facilities compound these medicines at scale. The agency's own language is unambiguous: 'when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.' Public comment closed on 29 June 2026, and the direction of travel is now hard to mistake, arriving just as semaglutide online search volume keeps climbing.

This is precisely why U.S. News drew its line where it did. Excluding compounded-only providers from a ratings launch six weeks after a study documenting their prescribing shortcuts, while the FDA is simultaneously closing the compounding pathway that supplies them, is not a coincidence of timing, it is a single regulatory and reputational current moving in one direction.

Platforms that spent 2024 and 2025 building a GLP-1 telehealth business around cheaper compounded alternatives are now being squeezed from two sides at once: the legal supply and the credible ratings both point the same way. Every compounded knockoff sold at a discount is still competing against a semaglutide online searcher who, the data shows, faces almost no credible content answering the question honestly.

Expect consolidation to follow. When a legal supply route narrows this sharply, smaller platforms built entirely around cheap compounded product tend to either add a branded offering fast, partner with an existing pharmacy network, or exit the category altogether. That reshuffling is itself a ratings opportunity: a platform that can credibly say it never relied on the compounding exception in the first place has a transparency story to tell that its rivals currently cannot.

Compounding itself is not the villain here, it is a legitimate, tightly regulated practice that the FDA's own guidance permits precisely because some patients need a dose or formulation the branded product does not offer. The problem was scale: outsourcing facilities registered under the FDA's 503B programme were compounding GLP-1s by the hundreds of thousands of units, well beyond the narrow clinical-need exception the rule was written for.

None of this sits apart from the wider data-privacy scrutiny healthcare marketers already face, a pattern the pixel became the liability already mapped in detail, and a GLP-1 telehealth platform now under a ratings spotlight is exactly the kind of brand a regulator or a journalist will pixel-audit first.

The Prescribing-Error Data Nobody Marketed Around#

If the JAMA secret-shopper study shows how loosely some sites solicit a prescription, a separate piece of research shows what goes wrong once the prescribing itself begins. A retrospective analysis published in Healthcare (Basel) audited 37,323 GLP-1 receptor agonist orders from a multidisciplinary digital weight-loss service across six months, from April to October 2023, and found an overall prescribing error rate of 4.4%, 1,654 orders out of the full set, a track record every platform selling semaglutide online has to reckon with.

That is a real-world proxy for what happens inside plenty of GLP-1 telehealth workflows, even if this particular service was never one of JAMA's secret shoppers.

What the breakdown actually shows#

Break that 4.4% down and the picture sharpens. Insufficient safety counselling accounted for 49.15% of all errors, inadequate contraindication checks for another 30.29%, incorrect dosing for 11.31%, and titration errors for the remaining 9.25%. Patients with a BMI of 40 or above, the group with the least room for a dosing mistake, were over 25% more likely to receive an erroneous prescription than lower-BMI patients. Counselling, in other words, is where the category is quietly failing most, not the dose itself.

Read against the six U.S. News pillars, that breakdown lands almost too neatly: insufficient safety counselling is a clinical-support failure, and inadequate contraindication checks is a screening-rigour failure, the two heaviest-weighted pillars in the entire scorecard. A platform can spend heavily on paid acquisition and still fail the pillars that matter most, a pattern the $262m headline that points the wrong way already unpacked for healthcare marketing budgets broadly: spend does not substitute for structure.

Notice what is absent from that error breakdown: technology failures, staffing shortages, anything a bigger engineering budget would fix. Every one of the four categories, counselling, contraindications, dosing, titration, is a conversation problem before it is a systems problem. That is uncomfortable for an industry that has spent heavily on app polish and comparatively little on the length and quality of the actual clinical conversation.

None of this means GLP-1 medicines are unsafe when properly prescribed. The underlying drugs carry an established, monitored safety profile that the FDA's own semaglutide safety page documents in detail. What the data shows is a delivery problem, not a drug problem, and delivery is exactly what a platform selling semaglutide online controls.

How a Platform Actually Earns a Strong Rating#

None of the above is an argument for panic, it is an argument for precision. A GLP-1 telehealth brand that wants to earn genuine best glp-1 online searches, and the much larger pool of semaglutide online searches sitting almost uncontested beside them, rather than buy them, has a short, unglamorous list of things to fix, and none of it involves trying to outfox the judges. It involves earning the same six pillars they already published. Being the best online glp-1 provider is no longer a claim a brand can just make about itself, it is something twenty judges just checked.

The pillars reward exactly the behaviour the JAMA and Healthcare (Basel) studies show is missing: real screening, real counselling, and real clarity about cost. Transparency and insurance assistance together account for 32% of the total score, and both are winnable with plain language rather than a bigger budget. State the list price for a patient searching glp-1 without insurance, or searching semaglutide online, in the first paragraph a prospective patient reads, not buried in a support article three clicks away.

Explain manufacturer savings cards, prior authorisation timelines and what happens if cover lapses mid-course. A platform that hides its pricing until checkout is optimising for the exact behaviour the transparency pillar is built to catch. Talking about safety credibly means naming the screening step, not just claiming to have one: say how many minutes a clinical review takes, whether it includes a video visit, and what disqualifies a patient.

The same disclosure discipline plays out elsewhere too, as how Snap built a door for the fine print, and pharma walked through it already showed, and the lesson transfers directly: patients and regulators both reward a brand that puts the caveat where the claim is.

The pillars, mapped to action#

That table is the whole brief, really: earn the heaviest pillars first and the satisfaction score tends to follow rather than lead. A fox does not build trust with the henhouse by shouting from the hedgerow, it earns a quiet path in over time, one uneventful visit after another. A well-run platform does not need a bigger den, just a tidier one: clear pricing, clear screening, clear proof. If your GLP-1 telehealth brand needs that pillar-by-pillar work translated into a real content and brand strategy, folkfox's content marketing team inside healthcare marketing builds exactly this, or you can simply start the conversation.

Frequently asked questions#